Latest Sales Growth News

Lumos Diagnostics reported a 21% quarter-on-quarter revenue increase in Q3 FY25, driven by strong product sales and expanded development agreements. The company also secured Medicare coverage in key US regions and advanced its pivotal FebriDx CLIA waiver study with FDA submission expected by year-end.

Aroa Biosurgery reports a second consecutive quarter of positive operating cash flow and record sales for its Myriad product line, while maintaining full-year FY25 revenue and EBITDA guidance.

Decidr AI Industries signals a strategic pivot to AI with a successful $11 million capital raise, new multi-year contracts, and expanded global partnerships, driving early commercial traction and robust e-commerce growth.

Dubber Corporation Limited reported a 6% quarter-on-quarter revenue increase to $11 million in Q3 FY25, alongside a 7% reduction in cash-based costs, positioning the company to achieve operating cash flow breakeven by June 2025.

James Hardie Industries plc reported a 3% decline in Q3 FY25 net sales to $953 million and a 15% drop in adjusted net income to $154 million, yet reaffirmed its full-year guidance and outlined ambitious growth plans for FY26.

EBOS Group Limited posted robust interim results for H1 FY25, with underlying EBITDA rising 7.1% excluding the Chemist Warehouse Australia contract, driven by strong organic growth and strategic investments. The company maintained its dividend and reiterated FY25 EBITDA guidance between $575 million and $600 million.

EBOS Group Limited posted a strong half-year performance with underlying EBITDA up 7.1% to $291 million, driven by growth in healthcare and animal care segments, while maintaining its interim dividend amid the loss of the Chemist Warehouse contract.

XRF Scientific has reported record half-year revenue and profit for FY25, driven by robust demand from mining and industrial sectors and strategic acquisitions that bolster its market position.

XRF Scientific has reported a record half-year performance, driven by robust mining sector demand and strategic sales growth across its divisions.

XRF Scientific Limited reported a robust half-year performance ending December 2024, with revenue edging up 0.3% to $28.7 million and net profit after tax surging 11.8% to $5.0 million, driven by strong consumables sales and international growth.

ARB Corporation Limited posted a 5.9% rise in sales revenue to $361.7 million for 1H FY2025, driven by strong export growth, while profit before tax edged down 0.7% amid rising costs and subdued domestic vehicle sales.

ARB Corporation Limited reported a 5.9% increase in sales revenue to $361.7 million for the half year ended December 2024, while profit margins slightly contracted. Strategic acquisitions in the US and Australasia underpin the company’s cautious optimism for future growth.